kidney disease

A ballpoint pen rests on top of a stack of documents ready for signing

Boehringer continues kidney dealmaking with $120M Variant pact

Boehringer unveiled its second kidney-focused collab in recent weeks, this time penning a deal worth up to $120 million with genomics-focused Variant.

James Waldron Jan 6, 2026 10:45am

Akebia promises $12M for Q32’s rare kidney disease candidate

Dec 1, 2025 9:45pm

Biogen returns to its roots with a West Coast immunology outpost

Nov 18, 2025 12:25pm

AbbVie to end Calico collab, lay off scientists: Stat

Nov 13, 2025 3:59pm

Otsuka's kidney disease drug halves UPCR levels in ph. 3 study

Jun 6, 2025 6:26am

MA strategy deal block push come together form

Amicus pays Dimerix $30M for late-phase rare kidney disease drug

May 1, 2025 10:59am